Cellyrix leverages an advanced computational pipeline integrated with high-throughput experimental screening to discover and develop therapeutics that facilitate transitions from aggressive cell states to less malignant ones.

The company is pioneering targeted therapies tailored to combat resistant cell states, guided by biomarkers derived from the cell state composition of tumors.Cellyrix serves as a platform for the development of therapeutics that facilitate transitions between therapy-resistant and aggressive cell states to more responsive and less malignant ones.